Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an ...

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

Coherus BioSciences (CHRS) announced the completion of the previously announced divestiture of its UDENYCA franchise to Intas Pharmaceuticals ...

Shares of California-based Coherus BioSciences (Nasdaq: CHRS) rose more than 5% to $0.88 in pre-market activity today as it ...

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for the Simponi (golimumab) biosimilar, BAT2506 in the US. Bio-Thera will develop ...

This came after Intas Pharmaceuticals presented the proposal to conduct phase III Clinical trial titled: “A Single Group, Non ...

– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

In the latest in a growing trend of pharma reshuffling moves in Asia, Marubeni Corporation is absorbing Sumitomo Pharma’s ...

Intas Pharma becomes most valuable privately held pharma company A PE deal values Intas at Rs 23,000 crore or USD 3.5 billion, making it the most valued pharma privately held company in India.

Ahmedabad: Intas Pharma has announced the appointment of Parthiv Mehta as the new Vice President - Rest of Africa & International Fertility."We are delighted to welcome Parthiv Mehta as ...

Ahmedabad based Intas Pharma which is a closely held company buys Tava's European assets for USD 764 million in an all cash deal. CNBC-TV18's Nisha Poddar spoke with Binish Chudgar, MD of Intas ...

Aurobindo's latest bid comes on the heels of last month’s shot at Israeli drug maker Teva's UK product portfolio, where it was outbid by rival Intas Pharmaceuticals. Intas buys Teva's UK ...